 |
Photo = Yonhap news |
[Alpha Biz= Kim Jisun] The "Group of Four" coalition, the largest shareholder group of Hanmi Science, has reached an agreement with shareholder Lim Jong-yoon, the eldest son of Hanmi Pharmaceutical Group's late founder Lim Sung-ki, to establish a sustainable management system.
According to Hanmi Pharmaceutical Group on Thursday, Lim, along with his mother, Hanmi Pharmaceutical Group Chairwoman Song Young-sook, his elder sister and Vice Chairwoman Lim Joo-hyun, and private largest shareholder Shin Dong-kook, Chairman of Hanyang Precision, as well as Killington Co., Ltd. (La Défense), issued a joint press release announcing the resolution of their management dispute. The Group of Four purchased a 5% stake owned by Lim. Both sides agreed to work together to stabilize the group’s governance and establish a sustainable management system centered on professional managers.
The parties stated, “We will set aside all conflicts and divisions and unite our hearts solely for Hanmi’s growth. We will reward shareholders through ethical management and enhancing corporate value.” With the acquisition of Lim's stake, the Group of Four's stake has increased to 40%. Including shares held by the Gahyeon Cultural Foundation and the Lim Sung-ki Foundation, their stake reaches 48%. Lim Jong-yoon retains an 11.79% stake, while his younger brother, Lim Jong-hoon, CEO of Hanmi Science, holds 7.85%.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
